4 results match your criteria: "Amrita School for Nanosciences and Molecular Medicine[Affiliation]"
Lett Appl Microbiol
January 2025
Amrita School for Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi 682041, India.
Mycobacterium marinum is a slow growing Non-Tuberculosis Mycobacteria known to cause skin and subcutaneous tissue infections known as "fish tank granuloma" in humans. Treatment of M. marinum skin infections can last for several months or even years.
View Article and Find Full Text PDFMol Divers
August 2024
Bioinformatics and Computational Biology Lab, Amrita School for Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala State, 682 041, India.
PD-L1 is a key immunotarget involved in binding to its receptor PD-1. PD-L1/PD-1 interface blocking using antibodies (or small molecules) is the central area of interest for tumor suppression in various cancers. Blocking the PD-L1/PD-1 pathway in the tumor cells results in its immune activation and destruction, and thereby restoring the T-cell proliferation and cytokine production.
View Article and Find Full Text PDFNano Lett
June 2023
School of Chemical Engineering and Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland 4072, Australia.
BiSe is a semiconductive material possessing a bandgap of 0.3 eV, and its unique band structure has paved the way for diverse applications. Herein, we demonstrate a robust platform for synthesizing mesoporous BiSe films with uniform pore sizes via electrodeposition.
View Article and Find Full Text PDFMol Inform
June 2023
Bioinformatics and Computational Biology Lab, Amrita School for Nanosciences and Molecular Medicine Amrita Vishwa Vidyapeetham, Kochi, 682 041, Kerala State, INDIA.
PD-1/PD-L1 is a critical druggable target for immunotherapy against sepsis. Chemoinformatics techniques involved the structure-based 3D pharmacophore model development followed by virtual screening of small molecule databases to identify the small molecules against PD-L1 pathway inhibition. Raltitrexed and Safinamide act as potent repurposed drugs, and three other Specs database compounds using in silico methods.
View Article and Find Full Text PDF